Biocartis - Merck partnership for colorectal cancer diagnostics

January 11, 2016 News BioVox

Biocartis closed a deal with Merck KGaA (Merck) for the development and commercialization of a new liquid biopsy RAS biomarker test for patients with metastatic colorectal cancer (mCRC). A patients’ individual biomarker status allows to quickly make a decision on which treatment should be used.

The test will be used on Idylla™, a fully automated sample-to-result PCR-based molecular diagnostics system. The Idylla™ RAS test will be able to detect an extended panel of RAS mutations, in addition to a BRAF V600 mutation.

Biocartis and Merck plan to introduce the Idylla™ liquid biopsy RAS test in numerous medical centers across the world, excluding the U.S., China and Japan. At first, the test will be available for Research Use Only (RUO), but will be submitted to obtain a CE Mark shortly thereafter.

Avatar photo

With a local focus and global reach, BioVox shares insights into the Belgian life sciences ecosystem with an ever-growing global community. BioVox is a non-profit project: we are able to provide our community with free, quality content because of the generous support of Turnstone Communications and its clients. Our articles bring you hidden opportunities and exclusive insights into the latest research and industry trends!

All posts